FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB	APPROVAL

OMB Number: 3235-0287 Estimated average burden 0.5 hours per response

# Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					or S	Section 30	O(h) of the I	nvestme	ent Co	mpany Act o	f 1940						
1. Name and Address of Reporting Person*  TREU JESSE I				2. Issuer Name <b>and</b> Ticker or Trading Symbol  TANDEM DIABETES CARE INC [ TNDM ]							] (Ched	S. Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director X 10% Owner     Officer (give title Other (specify)					
(Last) (First) (Middle) C/O DOMAIN ASSOCIATES, LLC ONE PALMER SQUARE						3. Date of Earliest Transaction (Month/Day/Year) 11/19/2013							Officer (gi below)	ive title		other ( below)	
(Street) PRINCETON NJ 08542				4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person					
(City) (State) (Zip)																	
			Table I - Noi			_		_	, Dis								
1. Title of Security (Instr. 3)				2. Transa Date (Month/D		) if any	emed tion Date, n/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed O					6. Owner Form: Di (D) or Inc (I) (Instr.	Direct ndirect tr. 4)	7. Nature of Indirect Beneficial Ownership
									Code V Amo		nount (A) or (D)		Transaction( (Instr. 3 and				(Instr. 4)
Common Stock			11/19/	9/2013		С		3,189,05	8 A	(1)	3,189,058		I		By Domain Partners VII, L.P.		
Common Stock			11/19/	)/2013			С		54,390	A	(1)	54,390		I		By DP VII Associates, L.P.	
			Table II -							osed of, c			wned				
Derivative			3A. Deemed Execution Date,	e, Transaction Code (Instr. 8)		5. Number of Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		cisable and	7. Title an	d Amount of Underlying Security	unt of 8. Price of Derivative		9. Number of derivative Securities Beneficially Owned Following		11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	Amount or Number of Shares	Repo Trans (Instr		action(s)		
Series B Preferred Stock	(1)	11/19/2013		С			356,111	(1)		(1)	Common Stock	356,111	\$0	0		I	By Domain Partners VII, L.P.
Series C Preferred Stock	(1)	11/19/2013		С			549,833	(1	.)	(1)	Common Stock	549,833	\$0	C	0		By Domain Partners VII, L.P.
Series D Preferred Stock	(1)	11/19/2013		С			2,283,114	(1	.)	(1)	Common Stock	2,283,114	\$0	0		I	By Domain Partners VII, L.P.
Warrant to Purchase Series D Preferred Stock	\$4.4	11/19/2013		J <sup>(2)</sup>			590,403	(3	))	(3)	Series D Preferred Stock	590,403	\$0	C	0		By Domain Partners VII, L.P.
Warrant to Purchase Common Stock	\$7.37	11/19/2013		J <sup>(2)</sup>		352,351		(4	1)	(4)	Common Stock	352,351	\$0	352,	,351	I	By Domair Partners VII, L.P.
Series B Preferred Stock	(1)	11/19/2013		С			6,071	(1	.)	(1)	Common Stock	6,071	\$0	C	)	I	By DP VII Associates, L.P.
Series C Preferred Stock	(1)	11/19/2013		С	Ш		9,378	(1	.)	(1)	Common Stock	9,378	\$0	C	)	I	By DP VII Associates, L.P.
Series D Preferred Stock	(1)	11/19/2013		С	Ш		38,941	(1	.)	(1)	Common Stock	38,941	\$0	C	)	I	By DP VII Associates, L.P.
Warrant to Purchase Series D Preferred Stock	\$4.4	11/19/2013		J <sup>(2)</sup>			10,068	(5	i)	(5)	Series D Preferred Stock	10,068	\$0	C	)	I	By DP VII Associates, L.P.
Warrant to Purchase Common Stock	\$7.37	11/19/2013		<b>J</b> (2)		6,008		(6	5)	(6)	Common Stock	6,008	\$0	6,0	008	I	By DP VII Associates, L.P.

### **Explanation of Responses:**

- 1. All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The preferred stock had no expiration date. The Common Stock equivalents of the preferred stock reflect the 1 for 1.6756 reverse split of the Common Stock effected in November 2013.
- 2. Upon the closing of the IPO the Warrants to purchase Series D Preferred Stock automatically converted into Warrants to purchase the number of shares of Common Stock that the Series D Preferred Stock underlying the

Warrants were convertible into, subject to the reverse split described in footnote (1), and the exercise price accordingly adjusted to \$7.37 per share.

- 3. The Warrant to purchase Series D Preferred Stock was immediately exercisable and expired as follows: 362,965 shares on 8/17/21; 90,741 shares on 5/25/22; and 136,697 shares on 7/17/22.
- 4. The Warrant to purchase Common Stock is immediately exercisable and expires as follows: 216,617 shares on 8/17/21; 54,154 shares on 5/25/22; and 81,580 shares on 7/17/22.
- $5. \ The Warrant to purchase Series D Preferred Stock was immediately exercisable and expired as follows: \\ 6,190 \ shares on \\ 8/17/21; \\ 1,547 \ shares on \\ 5/25/22; \ and \\ 2,331 \ shares on \\ 7/17/22.$
- 6. The Warrant to purchase Common Stock is immediately exercisable and expires as follows: 3,694 shares on 8/17/21; 923 shares on 5/25/22; and 1,391 shares on 7/17/22.

## Remarks:

/s/Kathleen K. Schoemaker, Attorney-in-Fact

11/19/2013

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.